CA2962239C - Uses of trehalose in cell suspensions - Google Patents

Uses of trehalose in cell suspensions Download PDF

Info

Publication number
CA2962239C
CA2962239C CA2962239A CA2962239A CA2962239C CA 2962239 C CA2962239 C CA 2962239C CA 2962239 A CA2962239 A CA 2962239A CA 2962239 A CA2962239 A CA 2962239A CA 2962239 C CA2962239 C CA 2962239C
Authority
CA
Canada
Prior art keywords
cells
trehalose
cell suspension
cell
thawed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2962239A
Other languages
English (en)
French (fr)
Other versions
CA2962239A1 (en
Inventor
Erik John Woods
Sreedhar Thirumala
Shelly J. Zacharias
Matthew B. Welty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gallant Pet Inc
Original Assignee
Gallant Pet Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gallant Pet Inc filed Critical Gallant Pet Inc
Publication of CA2962239A1 publication Critical patent/CA2962239A1/en
Application granted granted Critical
Publication of CA2962239C publication Critical patent/CA2962239C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
CA2962239A 2014-09-29 2015-09-29 Uses of trehalose in cell suspensions Active CA2962239C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462056842P 2014-09-29 2014-09-29
US62/056,842 2014-09-29
PCT/US2015/052950 WO2016069173A2 (en) 2014-09-29 2015-09-29 Uses of trehalose in cell suspensions

Publications (2)

Publication Number Publication Date
CA2962239A1 CA2962239A1 (en) 2016-05-06
CA2962239C true CA2962239C (en) 2024-01-02

Family

ID=55583355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2962239A Active CA2962239C (en) 2014-09-29 2015-09-29 Uses of trehalose in cell suspensions

Country Status (8)

Country Link
US (2) US20160089401A1 (https=)
EP (1) EP3201319A4 (https=)
JP (1) JP2017531446A (https=)
CN (1) CN107106488A (https=)
AU (1) AU2015339886B2 (https=)
BR (1) BR112017006533A2 (https=)
CA (1) CA2962239C (https=)
WO (1) WO2016069173A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190231694A1 (en) * 2016-10-12 2019-08-01 Agency For Science, Technology And Research Method for lyophilising an exosome
GB201716729D0 (en) * 2017-10-12 2017-11-29 Asymptote Ltd Cryopreservation method and apparatus
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
EP4146787A4 (en) 2020-05-08 2024-06-26 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
CN111856022A (zh) * 2020-07-01 2020-10-30 山东凯歌智能机器有限公司 一种检测胰腺癌患者外周血循环肿瘤细胞E-Cadherin表达的试剂盒及检测方法
CN111638341A (zh) * 2020-07-01 2020-09-08 山东凯歌智能机器有限公司 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
EP4262385A1 (en) 2020-12-19 2023-10-25 Khorakiwala, Habil F Lyophilized mesenchymal stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1188171C (zh) * 1994-06-02 2005-02-09 廓德伦特控股剑桥有限公司 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物
DE59804785D1 (de) * 1997-11-22 2002-08-22 Roche Diagnostics Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
US20060134596A1 (en) * 2003-05-08 2006-06-22 Anita Sjogren Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
EP1841856A1 (en) * 2005-01-28 2007-10-10 Canadian Blood Services A method of cryopreserving cells and tissues by liposomal delivery of sugars to enhance post-thaw viability
US20090029340A1 (en) * 2006-01-04 2009-01-29 Do-Coop Technologies Ltd. Cryoprotective Compositions and Methods of Using Same
KR20200011604A (ko) * 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
CA2768613A1 (en) * 2009-07-20 2011-01-27 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for improving the viability of cryopreserved cells
WO2012030968A1 (en) * 2010-08-31 2012-03-08 Renovocyte, LLC Systemic, allogenic stem cell therapies for treatment of diseases in animals
JP5341059B2 (ja) * 2010-11-09 2013-11-13 株式会社大塚製薬工場 幹細胞懸濁液
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
JP5432322B2 (ja) * 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
JP5196618B1 (ja) * 2012-09-28 2013-05-15 株式会社大塚製薬工場 トレハロース含有細胞洗浄溶液を用いた接着細胞の洗浄方法
CN104161037B (zh) * 2014-08-13 2016-01-13 江苏丘陵地区镇江农业科学研究所 一种山羊精液玻璃化冷冻和解冻配方与方法
CN105052894B (zh) * 2015-08-26 2018-03-06 中国农业科学院特产研究所 一种gv期卵母细胞冷冻保存液及冷冻保存方法

Also Published As

Publication number Publication date
CA2962239A1 (en) 2016-05-06
BR112017006533A2 (pt) 2017-12-19
WO2016069173A3 (en) 2016-07-28
US20210252155A1 (en) 2021-08-19
EP3201319A2 (en) 2017-08-09
AU2015339886B2 (en) 2019-05-09
EP3201319A4 (en) 2018-05-16
CN107106488A (zh) 2017-08-29
JP2017531446A (ja) 2017-10-26
WO2016069173A2 (en) 2016-05-06
AU2015339886A1 (en) 2017-04-13
US20160089401A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
CA2962239C (en) Uses of trehalose in cell suspensions
KR101868653B1 (ko) 줄기 세포 현탁액
US8642255B2 (en) Materials and methods for hypothermic collection of whole blood
US20260007702A1 (en) Stem cell therapy based on adipose-derived stem cells
CN104873542A (zh) 一种脐带间充质干细胞注射液及其制备方法和应用
US20200383317A1 (en) Viable cell compositions, and methods related to same
WO2013168403A1 (ja) トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
WO2014203268A2 (en) Method for isolation, purification and industrial scale expansion of equine adipose tissue derived mensenchymal stem cells
JP5753874B2 (ja) 細胞生存率低下抑制剤
WO2013168402A1 (ja) デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
JP2022159210A (ja) 凍結接着性幹細胞の製造方法
CA3022685C (en) Methods of cryopreservation of viable cells, compositions of viable cells and uses thereof
EP4281131A1 (en) Methods for optimizing reproductive tissue derived cell yield and viability for clinical applications
WO2022210574A1 (ja) 筋ジストロフィー治療剤
JP2023148207A (ja) 細胞製剤用非凍結保存液
HK1152841B (en) Materials and methods for hypothermic collection of whole blood

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200925

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240813

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240813

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919